Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Tissue culture for neoplastic disorders; solid tumor

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 88239 refers to a laboratory procedure known as tissue culture for neoplastic disorders, specifically focusing on solid tumors. This procedure involves the cultivation of cells and/or tissue samples that are suspected to be involved in neoplastic disorders, which are conditions characterized by the abnormal growth of cells, often leading to tumors. The primary objective of this test is to analyze the genetic material within these cells to identify various chromosomal abnormalities, hereditary genotypes, mutations, phenotypes, and karyotypes. Such analyses are crucial for diagnosing neoplastic conditions, determining the prognosis of the disease, and monitoring the progression or response to treatment of hematopoietic diseases, which affect blood-forming tissues. To perform this test, whole blood is typically collected through a venipuncture, which is a separately reportable procedure. Additionally, bone marrow samples can be obtained via aspiration, also a separately reportable procedure. For solid tumors, tissue samples such as those from lymph nodes are acquired through excision or biopsy methods. The laboratory utilizes specific staining techniques, such as Giemsa Band, to evaluate whole blood and solid tissue samples. In the case of bone marrow, testing may involve Giemsa Band or advanced techniques like cell culture fluorescence in situ hybridization, which allows for detailed visualization of genetic material. This comprehensive approach ensures that healthcare providers have the necessary information to make informed decisions regarding patient care and treatment strategies.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The procedure associated with CPT® Code 88239 is indicated for the following conditions:

  • Neoplastic Disorders The test is performed when there is a suspicion or confirmation of neoplastic disorders, which may include various types of tumors.
  • Diagnosis It aids in the diagnosis of hematopoietic diseases by providing critical genetic information.
  • Prognosis The results can help in determining the prognosis of the disease, guiding treatment decisions.
  • Monitoring It is used for monitoring the progression of hematopoietic diseases and assessing the effectiveness of ongoing treatments.

2. Procedure

The procedure for CPT® Code 88239 involves several key steps that ensure the accurate collection and analysis of tissue samples.

  • Step 1: Sample Collection The first step involves obtaining the necessary samples for testing. Whole blood is collected through a venipuncture, which is a procedure where a needle is inserted into a vein to draw blood. This step is crucial as it provides a source of cells for genetic analysis. Additionally, bone marrow is obtained through a separate aspiration procedure, where a needle is inserted into the bone to extract marrow. For solid tumors, tissue samples, such as those from lymph nodes, are collected via excision or biopsy, which involves removing a small section of tissue for examination.
  • Step 2: Laboratory Processing Once the samples are collected, they are sent to the laboratory for processing. The laboratory utilizes specific staining techniques, such as Giemsa Band, to prepare the whole blood and solid tissue samples for analysis. This staining allows for the visualization of chromosomes and other genetic material within the cells. In the case of bone marrow samples, additional techniques like cell culture fluorescence in situ hybridization may be employed to provide a more detailed analysis of the genetic content.
  • Step 3: Analysis and Reporting After processing, the laboratory conducts a thorough analysis of the samples. This includes identifying chromosomal abnormalities, mutations, and other genetic factors that are relevant to the neoplastic disorder. The results are then compiled into a report that is provided to the healthcare provider, who will use this information to make informed decisions regarding diagnosis, treatment, and monitoring of the patient's condition.

3. Post-Procedure

Post-procedure care for patients undergoing the tissue culture for neoplastic disorders typically involves monitoring for any potential complications related to the sample collection, particularly from venipuncture or bone marrow aspiration. Patients may experience some discomfort or bruising at the site of blood draw or aspiration. It is important for healthcare providers to provide patients with instructions on how to care for the site and to inform them about signs of infection or excessive bleeding that may require medical attention. Additionally, patients should be informed about the timeline for receiving results from the laboratory, as this can vary based on the complexity of the analysis performed. Follow-up appointments may be scheduled to discuss the results and any necessary next steps in the management of the neoplastic disorder.

Short Descr TISSUE CULTURE TUMOR
Medium Descr TISS CUL NEO DISORDERS SOLID TUMOR
Long Descr Tissue culture for neoplastic disorders; solid tumor
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 3
CCS Clinical Classification 206 - Microscopic examination (bacterial smear, culture, toxicology)
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
GC This service has been performed in part by a resident under the direction of a teaching physician
GZ Item or service expected to be denied as not reasonable and necessary
X3 Episodic/broad services: for reporting services by clinicians who have broad responsibility for the comprehensive needs of the patient that is limited to a defined period and circumstance such as a hospitalization; reporting clinician service examples include but are not limited to the hospitalist's services rendered providing comprehensive and general care to a patient while admitted to the hospital
Date
Action
Notes
2011-01-01 Changed Short description changed.
Pre-1990 Added Code added.
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"